378 related articles for article (PubMed ID: 33880507)
41. Tacrolimus Combined with Corticosteroids Improved the Outcome of CIDP Patients with Autoantibodies Against Paranodal Proteins.
Yang MG; Xu L; Ji S; Gao H; Zhang Q; Bu B
Neuropsychiatr Dis Treat; 2022; 18():1207-1217. PubMed ID: 35734550
[TBL] [Abstract][Full Text] [Related]
42. Contactin-1 and Neurofascin-155/-186 Are Not Targets of Auto-Antibodies in Multifocal Motor Neuropathy.
Doppler K; Appeltshauser L; Krämer HH; Ng JK; Meinl E; Villmann C; Brophy P; Dib-Hajj SD; Waxman SG; Weishaupt A; Sommer C
PLoS One; 2015; 10(7):e0134274. PubMed ID: 26218529
[TBL] [Abstract][Full Text] [Related]
43. Paranodal destruction and axo-glial dysjunction in a subtype of CIDP with anticontaction-1 antibodies.
Kuwabara S; Misawa S; Mori M
J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):707. PubMed ID: 25758172
[No Abstract] [Full Text] [Related]
44. Case report: Immunoadsorption therapy for anti-caspr1 antibody-associated nodopathy.
Liu L; Chen J; Zhang Y; Wu J; Hu J; Lin Z
Front Immunol; 2022; 13():986018. PubMed ID: 36211443
[TBL] [Abstract][Full Text] [Related]
45. [Antibodies in patients with chronic inflammatory demyelinating polyneuropathy].
Mohamed A; Krøigård T; Gaist TA; Markvardsen LK; Sindrup S; Andersen H; Blaabjerg M
Ugeskr Laeger; 2018 Dec; 180(49):. PubMed ID: 30520721
[TBL] [Abstract][Full Text] [Related]
46. Autoimmune nodopathies, an emerging diagnostic category.
Martín-Aguilar L; Lleixà C; Pascual-Goñi E
Curr Opin Neurol; 2022 Oct; 35(5):579-585. PubMed ID: 35989582
[TBL] [Abstract][Full Text] [Related]
47. Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism.
Kira JI
Front Neurol; 2021; 12():665136. PubMed ID: 34177770
[TBL] [Abstract][Full Text] [Related]
48. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.
Devaux JJ; Miura Y; Fukami Y; Inoue T; Manso C; Belghazi M; Sekiguchi K; Kokubun N; Ichikawa H; Wong AH; Yuki N
Neurology; 2016 Mar; 86(9):800-7. PubMed ID: 26843559
[TBL] [Abstract][Full Text] [Related]
49. Two CIDP Variants Patients With Anti-Caspr1 Antibodies in South China.
Li C; Zheng H; Yuan C; Li Y; Hu Y; Jiang H
Front Immunol; 2022; 13():844036. PubMed ID: 35359983
[TBL] [Abstract][Full Text] [Related]
50. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.
Querol L; Devaux J; Rojas-Garcia R; Illa I
Nat Rev Neurol; 2017 Sep; 13(9):533-547. PubMed ID: 28708133
[TBL] [Abstract][Full Text] [Related]
51. Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy.
Allen D; Giannopoulos K; Gray I; Gregson N; Makowska A; Pritchard J; Hughes RA
J Peripher Nerv Syst; 2005 Jun; 10(2):174-80. PubMed ID: 15958128
[TBL] [Abstract][Full Text] [Related]
52. Class and IgG subclass distribution of antibodies against peripheral nerve myelin in sera from patients with inflammatory demyelinating polyradiculoneuropathy.
Vedeler CA; Matre R; Nyland H
Acta Neurol Scand; 1988 Nov; 78(5):401-7. PubMed ID: 2464267
[TBL] [Abstract][Full Text] [Related]
53. Neurofascin antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: from intrinsic genetic background to clinical manifestations.
Wang Z; Zhou X; Zhao N; Xie C; Zhu D; Guan Y
Neurol Sci; 2021 Jun; 42(6):2223-2233. PubMed ID: 33782779
[TBL] [Abstract][Full Text] [Related]
54. Anti-LGI4 Antibody Is a Novel Juxtaparanodal Autoantibody for Chronic Inflammatory Demyelinating Polyneuropathy.
Zhang X; Kira JI; Ogata H; Imamura T; Mitsuishi M; Fujii T; Kobayashi M; Kitagawa K; Namihira Y; Ohya Y; Maimaitijiang G; Yamasaki R; Fukata Y; Fukata M; Isobe N; Nakamura Y
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36631269
[TBL] [Abstract][Full Text] [Related]
55. Clinical characteristics of patients with autoimmune nodopathy with anti-neurofascin155 antibodies.
Zhang J; Hou X; Wei L; Liu J; Li S; Guo Y; Liu H; Jiang Y
Front Immunol; 2024; 15():1345953. PubMed ID: 38726012
[TBL] [Abstract][Full Text] [Related]
56. Serum Contactin-1 in CIDP: A Cross-Sectional Study.
Wieske L; Martín-Aguilar L; Fehmi J; Lleixà C; Koel-Simmelink MJA; Chatterjee M; van Lierop Z; Killestein J; Verhamme C; Querol L; Rinaldi S; Teunissen CE; Eftimov F
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34285092
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial.
Shimizu S; Iijima M; Fukami Y; Tamura N; Nakatochi M; Ando M; Nishi R; Koike H; Kaida K; Koga M; Kanda T; Ogata H; Kira JI; Mori M; Kuwabara S; Katsuno M
JMIR Res Protoc; 2020 Apr; 9(4):e17117. PubMed ID: 32234705
[TBL] [Abstract][Full Text] [Related]
58. Anti-contactin 1 Antibody-associated Membranous Nephropathy in Chronic Inflammatory Demyelinating Polyneuropathy with Several Autoantibodies.
Shida R; Iwakura T; Ohashi N; Ema C; Aoki T; Tashiro T; Ishigaki S; Isobe S; Fujikura T; Kato A; Nakamura T; Fujigaki Y; Shimizu A; Yasuda H
Intern Med; 2024; 63(5):699-705. PubMed ID: 38432895
[TBL] [Abstract][Full Text] [Related]
59. Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies.
Dalakas MC
Neurotherapeutics; 2022 Apr; 19(3):741-752. PubMed ID: 35290608
[TBL] [Abstract][Full Text] [Related]
60. CIDP/autoimmune nodopathies with nephropathy: a case series study.
Tang Y; Liu J; Gao F; Hao H; Jia Z; Zhang W; Shi X; Liang W; Yu M; Lv H; Tan Y; Li Z; Wang Y; Yuan Y; Meng L; Wang Z
Ann Clin Transl Neurol; 2023 May; 10(5):706-718. PubMed ID: 36932648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
